- Home
- RIGL vs ALLT Comparison
RIGL vs ALLT Comparison
Compare RIGL & ALLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- ALLT
- Stock Information
- Founded
- RIGL 1996
- ALLT 1996
- Country
- RIGL United States
- ALLT Israel
- Employees
- RIGL N/A
- ALLT N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- ALLT Telecommunications Equipment
- Sector
- RIGL Health Care
- ALLT Telecommunications
- Exchange
- RIGL Nasdaq
- ALLT Nasdaq
- Market Cap
- RIGL 537.6M
- ALLT 458.2M
- IPO Year
- RIGL 2000
- ALLT 2006
- Fundamental
- Price
- RIGL $29.48
- ALLT $10.19
- Analyst Decision
- RIGL Buy
- ALLT Strong Buy
- Analyst Count
- RIGL 5
- ALLT 3
- Target Price
- RIGL $38.20
- ALLT $12.75
- AVG Volume (30 Days)
- RIGL 492.6K
- ALLT 430.1K
- Earning Date
- RIGL 11-04-2025
- ALLT 11-18-2025
- Dividend Yield
- RIGL N/A
- ALLT N/A
- EPS Growth
- RIGL N/A
- ALLT N/A
- EPS
- RIGL 5.43
- ALLT N/A
- Revenue
- RIGL $267,921,000.00
- ALLT $95,342,000.00
- Revenue This Year
- RIGL $59.93
- ALLT $10.44
- Revenue Next Year
- RIGL N/A
- ALLT $12.99
- P/E Ratio
- RIGL $5.44
- ALLT N/A
- Revenue Growth
- RIGL 105.62
- ALLT 4.74
- 52 Week Low
- RIGL $13.57
- ALLT $3.35
- 52 Week High
- RIGL $43.72
- ALLT $11.42
- Technical
- Relative Strength Index (RSI)
- RIGL 46.18
- ALLT 54.55
- Support Level
- RIGL $29.30
- ALLT $9.17
- Resistance Level
- RIGL $30.94
- ALLT $10.69
- Average True Range (ATR)
- RIGL 1.26
- ALLT 0.50
- MACD
- RIGL 0.38
- ALLT -0.05
- Stochastic Oscillator
- RIGL 53.61
- ALLT 59.02
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.